Drugs /

fludarabine

Back to Drugs List

Overview

Generic Name(s):
fludarabine
Trade Name(s):
Beneflur and Fludara
NCI Definition [1]:
A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. (NCI04)

Clinical Trials

View Clinical Trials for fludarabine

Fludarabine has been investigated in 352 clinical trials, of which 285 are open and 67 are closed. Of the trials investigating fludarabine, 8 are early phase 1 (6 open), 166 are phase 1 (142 open), 60 are phase 1/phase 2 (51 open), 90 are phase 2 (66 open), 1 is phase 2/phase 3 (1 open), 16 are phase 3 (13 open), 1 is phase 4 (1 open), and 10 are no phase specified (5 open).

del(5)(q10), Complex karyotype, and Monosomy 7 are the most frequent biomarker inclusion criteria for fludarabine clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia are the most common diseases being investigated in fludarabine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Fludarabine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Fludarabine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating fludarabine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Fludara, Beneflur, fludarabine, 2-f-araa, 2-fluoroadenine arabinoside, f-ara-a, fludarabine [chemical/ingredient], f ara a, fludarabine (substance), 2-fluoro ara-a, 9-beta-d-arabinofuranosyl-2-fluoroadenine, 9h-purin-6-amine, 9-beta-d-arabinofuranosyl-2-fluoro-, 2-fluorovidarabine, fluradosa, 9-beta-d-arabinofuranosyl-2-fluoro-9h-purin-6-amine, fludarabine, 2-fluoro-9-beta-arabinofuranosyladenine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, fludarabine (product)
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C1094
SNOMED ID [1]:
F-61B1A

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.